Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1786 • ACR Convergence 2023
Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis
Lu Bai¹, Chengkai Zhu¹, Yihong Xu², Kunhai Tang¹, Dachun Zhuo¹, Qing Zhang¹, Chengchun Geng¹, Weidong Xu², Hao Wu¹, Xingdong Chen¹ and Jiucun Wang¹, ¹Fudan University, Shanghai, China, ²Changhai Hospital, Shanghai, China
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory disease of the spinal joints leading to progressive loss of spinal mobility and chronic pain. Gutdysbiosis has been…
Abstract Number: 2546 • ACR Convergence 2023
Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up
CLARISSA PIMENTEL, ANA CRISTINA MEDEIROS-RIBEIRO, ANDREA SHIMABUCO, PERCIVAL SAMPAIO-BARROS, JULIO CESAR MORAES, CLAUDIA SCHAINBERG, CELIO GONÇALVES, ELAINE LEON, LEONARD KUPPA, Sandra Pasoto, NADIA AIKAWA, CLOVIS SILVA, Eloisa Bonfa and CARLA SAAD, University of São Paulo, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) therapies were one of the major advances in the treatment of Ankylosing Spondylitis (AS) patients. For infliximab, anti-drug antibodies…
Abstract Number: L14 • ACR Convergence 2022
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos¹, Atul Deodhar², Désirée van der Heijde³, Marina Magrey⁴, Walter Maksymowych⁵, Tetsuya Tomita⁶, Huji Xu⁷, Marga Oortgiesen⁸, Ute Massow⁹, Carmen Fleurinck¹⁰, Alicia M Ellis⁸, Tom Vaux¹¹, Julie Shepherd-Smith¹¹, Alexander Marten⁹ and Lianne S Gensler¹², ¹Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany, ²Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, US, Richfield, OH, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan, ⁷Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic), ⁸UCB Pharma, Morrisvile, NC, ⁹UCB Pharma, Monheim am Rhein, Nordrhein-Westfalen, Germany, ¹⁰UCB Pharma, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ¹¹UCB Pharma, Slough, United Kingdom, ¹²Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL‑17A. In the phase 3 BE MOBILE 1 and 2…
Abstract Number: 0383 • ACR Convergence 2022
Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA
Fabian Proft¹, Janis Vahldiek², Joeri Nicolaes³, Rachel Tham⁴, Bengt Hoepken⁵, Baran Ufuktepe⁶, Denis Poddubnyy¹ and Keno Kyrill Bressem², ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³UCB Pharma, Anderlecht, Belgium, ⁴UCB Pharma, Slough, UK, Overland Park, KS, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma A.S., Istanbul, Turkey
Background/Purpose: Conventional radiography of the sacroiliac joints is the first imaging method if axial spondyloarthritis (axSpA) is suspected. The presence of definite radiographic sacroiliitis is…
Abstract Number: 0414 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Xenofon Baraliakos¹, Fabiana Ganz², Hideto Kameda³, Jessica Walsh⁴, Manish Jain⁵, Kristin D’Silva⁶, Peter Wung⁶, Xianwei Bu⁶, Jayne Stigler⁶ and Désirée van der Heijde⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²AbbVie, Inc., Luzern, Switzerland, ³Toho University, Tokyo, Japan, ⁴University of Utah, Salt Lake City, UT, ⁵Great Lakes Clinical Trials, Chicago, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…
Abstract Number: 1005 • ACR Convergence 2022
Increasing the Proficiency for Scoring Sacroiliac Joint Radiographs According to the Modified New York Criteria for Ankylosing Spondylitis by Using an Online Real-time Iterative Calibration (RETIC) Module
Anna Hadsbjerg¹, Mikkel Østergaard², Joel Paschke³, Adrian Ciurea⁴, Michael Nissen⁵, Stephanie Wichuk⁶, Ashish J Mathew⁷, Marie Wetterslev⁸, Raphael Micheroli⁹, Susanne Pedersen¹⁰, Simon Krabbe¹⁰, Kristyna Bubova¹¹, Monika gregova¹², Alexander Bernatschek⁴, Maurice Donzallaz⁴, Burkhard Moeller¹³, Ziga Snoj¹⁴, Karlo Pintaric¹⁴, Manouk de Hooge¹⁵, Karel Gorican¹⁶, Robert G Lambert⁶ and Walter P Maksymowych¹⁷, ¹Copenhagen Center for Arthritis Research, COPECARE, Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ³CARE Arthritis LTD, Edmonton, AB, Canada, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Rigshospitalet, Copenhagen, Denmark, ⁸Rigshospitalet, Copenhagen, Glostrup, Denmark, ⁹University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland, ¹⁰Rigshospitalet, København, Denmark, ¹¹First Faculty of Medicine, Charles University,, Prague, Czech Republic, ¹²Institue of Rheumatology, Prague, ¹³Inselspital - University Hospital Bern, Bern, Switzerland, ¹⁴Radiology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁵Ghent University Hospital, Luxembourg, Luxembourg, ¹⁶MSK radiology unit, Radiology section – Diagnostic department, Geneva University Hospitals, Geneva, Switzerland, ¹⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiographic assessment of the sacroiliac joints (SIJ) according to the modified New York (mNY) criteria is essential in the classification of ankylosing spondylitis, but…
Abstract Number: 1158 • ACR Convergence 2022
Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
Chan Mi Lee¹, Maricela Haghiac² and Marina Magrey³, ¹University Hospitals, Cleveland, OH, ²Metrohealth Medical Center, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Richfield, OH
Background/Purpose: S100 proteins are a family of 25 calcium-binding cytosolic proteins which are involved in stress and inflammatory responses. S100A4 acts as a negative regulator…
Abstract Number: 1769 • ACR Convergence 2022
Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
Xenofon Baraliakos¹, Diego Kyburz², Jérôme Avouac³, Nick Barkham⁴ and Soohyun Lee⁵, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University Hospital Basel, Basel, Switzerland, ³University of Paris, Paris, France, ⁴New Cross Hospital, Telford, United Kingdom, ⁵Celltrion Healthcare, Incheon, Republic of Korea
Background/Purpose: The first subcutaneous (SC) formulation of infliximab (IFX) received approval for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), ankylosing…
Abstract Number: 0385 • ACR Convergence 2022
T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation
Michael Paley¹, Lynn Hassman², Grace Paley², Nicole Linskey², Philip Ruzycki², Jennifer Laurent², Lacey Feigl², Luke Springer² and Wayne Yokoyama², ¹Washington University in St. Louis, Saint Louis, MO, ²Washington University School of Medicine, St. Louis, MO
Background/Purpose: HLA-B27 is genetically linked to Axial Spondyloarthritis (axSpA) and anterior uveitis (AU), an inflammatory ocular disease that can lead to cataract, glaucoma, and permanent…
Abstract Number: 0415 • ACR Convergence 2022
The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis
Jean Liew¹, Timothy Treu², yojin Park², Jacqueline Ferguson³, Morgan Rosser², yuk-Lam Ho², Susan Heckbert⁴, Lianne Gensler⁵, Katherine Liao⁶ and Maureen Dubreuil⁷, ¹Boston University School of Medicine, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Stanford, Palo Alto, CA, ⁴University of Washington, Seattle, WA, ⁵Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Department of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: The increased cardiovascular (CV) disease burden in ankylosing spondylitis (AS) is established. Whether tumor necrosis factor inhibitor (TNFi) treatment, particularly when started early in…
Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1163 • ACR Convergence 2022
Proteomic Investigation to Identify Urinary Biomarker for Ankylosing Spondylitis
Ji-Hyun Lee¹, Jeesoo Kim², Sang-Hyon kim¹, Jong‑Seo kim² and Chang-Nam son¹, ¹Keimyung University, Dalseo-gu, Daegu, Republic of Korea, ²seoul national university, Seoul, Republic of Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the spine and peripheral joints, and the exact etiology is still unknown. Diagnosis…
Abstract Number: 2254 • ACR Convergence 2022
Detection of Active Inflammatory and Structural Changes Indicative of Axial Spondyloarthritis on MRI of Sacroiliac Joint Using a Deep Learning Framework
Keno Kyrill Bressem¹, Lisa Adams¹, Fabian Proft², Kay-Geert Hermann³, Torsten Diekhoff¹, Laura Spiller¹, Stefan Niehues¹, Marcus Makowski⁴, Bernd Hamm¹, Mikhail Protopopov⁵, valeria Rios-Rodriguez⁶, Hildrun Haibel⁷, Judith Rademacher⁵, Murat Torgutalp⁷, Robert G Lambert⁸, Xenofon Baraliakos⁹, Walter P Maksymowych¹⁰, Janis Vahldiek¹ and Denis Poddubnyy², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Technical University of Munich, Munich, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁸University of Alberta, Edmonton, AB, Canada, ⁹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁰Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Magnetic resonance tomography (MRI) plays a key role in the early diagnosis of axial spondyloarthritis (axSpA). However, the detection of changes indicative of axSpA…
Abstract Number: 0386 • ACR Convergence 2022
Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Mark Hwang¹, Jessica Castillo², kamala Vanarsa², Jim Zheng³, Shervin Assassi⁴, Chandra Mohan² and John Reveille⁵, ¹McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ²University of Houston, Houston, TX, ³UTHealth School of Bioinformatics, Houston, TX, ⁴McGovern Medical School, University of Texas, Houston, TX, ⁵University of Texas McGovern Medical School, Houston, TX
Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
Abstract Number: 0416 • ACR Convergence 2022
Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Casper Webers¹, Augusta Ortolan², Alexandre Sepriano³, Louise Falzon⁴, Xenofon Baraliakos⁵, Robert Landewé⁶, Sofia Ramiro⁷, Désirée van der Heijde⁸ and Elena Nikiphorou⁹, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²University of Padova/Leiden University Medical Center, Padova, Italy, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁹Leiden University Medical Center & King's College London, London, United Kingdom
Background/Purpose: Since the 2016 update of the management recommendations for axial spondyloarthritis (axSpA), new evidence has emerged on the efficacy and safety of biological disease-modifying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].